Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)
Alberto Fusi(Charité - Universitätsmedizin Berlin), Ulrich Keilholz(German Cancer Research Center), Sandra Collette(University of Turin), Cornelis J.A. Punt(Utrecht University), Alexander M.M. Eggermont(University Medical Center Utrecht), Angus Dalgleish(St George's, University of London), A. Rietz(Trinity College Dublin), Stefan Suciu(St James's University Hospital), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonia Busse(Franklin University), Alan Spatz(Jewish General Hospital), Wim H.J. Kruit(Erasmus MC), Alessandro Testori(European Organisation for Research and Treatment of Cancer)
Cited by 44
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k